References
- Moses H Jr, Brandes DW. Managing adverse effects of disease-modifying agents used for treatment of multiple sclerosis. Curr Med Res Opin 2008;24:2679-90
- Girouard N, Théorêt G. Management strategies for improving the tolerability of interferons in the treatment of multiple sclerosis. Can J Neurosci Nurs 2008;30:18-25
- Bayas A, Rieckmann P. Managing the adverse effects of interferon-β therapy in multiple sclerosis. Drug Safety 2000;22:149-59
- Frohman E, Phillips T, Kokel K, et al. Disease-modifying therapy in multiple sclerosis: strategies for optimizing management. Neurologist 2002;8:227-36
- Brandes D, Bigley K, Hornstein W, et al. Alleviating flu-like symptoms with dose titration and analgesics in MS patients on intramuscular interferon beta-1a therapy: a pilot study. Curr Med Res Opin 2007;23:1667-72
- Wroe SJ. Effects of dose titration on tolerability and efficacy of interferon beta-1b in people with multiple sclerosis. J Int Med Res 2005;33:309-18
- Pelletier J. Open-Label, randomised, parallel group study of Rebif 44 mcg administered 3 times weekly with or without initial titration in relapsing-remitting multiple sclerosis patients previously treated with low-dose interferon beta therapy. Presented at European Committee for Treatment and Research in Multiple Sclerosis 21st Congress; 28 September–1 October 2005; Thessaloniki, Greece. Poster 302
- Jacobs LD, Cookfair DL, Rudick RA, et al. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. Ann Neurol 1996;39:285-94
- Jacobs LD, Beck RW, Simon JH, et al. Intramuscular interferon beta-1a initiated during a first demyelinating event in multiple sclerosis. N Engl J Med 2000;343:898-904
- Kinkel RP, Kollman C, O’Connor P, et al. IM interferon beta-1a delays definite multiple sclerosis 5 years after a first demyelinating event. Neurology 2006;66:678-84
- Panitch H, Goodin DS, Francis G, et al. Randomized, comparative study of interferon β-1a treatment regimens in MS. The EVIDENCE Trial. Neurology 2002;59:1496-506
- Durelli L, Verdun E, Barbero P, et al. Every-other-day interferon beta-1b versus once-weekly interferon beta-1a for multiple sclerosis: results of a 2-year prospective randomised multicentre study (INCOMIN). Lancet 2002;359:1453-60
- Avonex [prescribing information]; Cambridge, MA, USA: Biogen Idec Inc., 2008
- Who gets MS? National MS Society. New York: National Multiple Sclerosis Society, 2011. Available at: http://www.nationalmssociety.org/about-multiple-sclerosis/what-we-know-about-ms/who-gets-ms/index.aspx [Last accessed 14 July 2011]
- Clarke J. Mechanisms of adverse drug reactions to biologics. In: Hofmann FB, Ganten D, Page CP Handbook of Experimental Pharmacology. Berlin and New York: Springer-Verlag, 2010. Vol. 196, part 3, 453-74
- Margolis K, Nichol KL, Poland GE, et al. Frequency of adverse reactions after influenza vaccination. Am J Med 1990;88:27-30
- Nadjar Y, Coutelas E, Prouteau P, et al. Injection of interferon-beta in the morning decreases flu-like syndrome in many patients with multiple sclerosis. Clin Neurol Neurosurg 2011;113:316-22
- Ali A, Owayed S, Al-Qabandi W, et al. Pegylated interferon alfa-2b plus ribavirin for the treatment of chronic hepatitis C genotyple 4 in adolescents. Ann Hepatol 2010;9:156-60
- Jara P, Hierro L, de al Vega A, et al. Efficacy and safety of peginterferon-α2b and ribavirin combination therapy in children with chronic hepatitis C infection. Pediatr Infect Dis J 2008;27:142-8